UbiQ

UbiQ was founded in 2010 as a spin-out of the Netherlands Cancer Institute (Amsterdam, The Netherlands). At UbiQ we develop and commercialize ubiquitin-based research tools, enabling drug discovery in the emerging ubiquitin field. Our products are targeted at pharmaceutical companies and academic research labs. Moreover, we develop assays for high-throughput screening, both for internal drug discovery projects and those partnered with pharmaceutical companies. Next to the reagent business, we have been focussing increasingly on our own drug discovery programs, based on novel technologies that we have recently developed. For example, we are rationally developing mechanism-based covalent inhibitors of the enzymes involved in protein SUMOylation. Many Myc-driven tumors appear to critically depend on hyper-SUMOylation. SUMOylation inhibitors can revert the hyper-SUMOylation state and thus specifically kill Myc-driven tumors. For more info on us or our products please visit: www.ubiqbio.com and www.sumiqtx.com